Price Crosses Moving Average
|Bid||128.90 x 900|
|Ask||129.50 x 1100|
|Day's Range||128.84 - 134.59|
|52 Week Range||115.03 - 217.25|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||11.02|
|Earnings Date||Aug 01, 2023 - Aug 07, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||216.67|
Subscribe to Yahoo Finance Plus to view Fair Value for MRNALearn more
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday. With this and earlier data, Moderna is considering seeking faster approval from regulators for the treatment, the company told investors after having presented the results at the American Society of Clinical Oncology meeting in Chicago. "Some of the residual uncertainty seems to be going away on that potential (option)," said Moderna President Stephen Hoge.
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced distant metastasis-free survival (DMFS) results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda for resected high-risk melanoma. The candidate is an investigational individualized neoantigen therapy. The companies recently announced the first presentation of the study's primary endpoint, recurrence-free survival, from the Phase 2 KEYNOTE-942/mRNA-4157-P201 trial in April 2023 at the American
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA,
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, follow earlier promising data from the trial showing the customized mRNA vaccine given in combination with Merck's Keytruda cut the risk of death or recurrence of melanoma by 44% compared with Keytruda alone. The findings add to a growing body of evidence suggesting that mRNA technology, which rose to prominence during the COVID-19 pandemic, can be used to assemble personalized vaccines that train the immune system to attack the specific type of cancer cells in a patient's tumors.
Key Insights Institutions' substantial holdings in Moderna implies that they have significant influence over the...
In this article, we will be taking a look at 10 stocks Jim Cramer and hedge funds have in common. To see more of these stocks, you can go directly to see 5 Stocks Jim Cramer and Hedge Funds Have In Common. “If You Use NVIDIA’s Chips, You Can Speak In The Vernacular Of ChatGPT” […]
The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:
Is Moderna stock a buy after the company reported a 19-cent gain in the first quarter vs. calls for losses? Is MRNA stock a buy?
The number of people with COVID-19 has been rising rapidly in China in recent weeks, and there are concerns that the government in Beijing could consider reviving its strict lockdown policies again. COVID-19 cases have been surging in China, largely due to the spread of the omicron XBB variants. In February, the Centers for Disease Control and Prevention pointed to early study results showing that for the bivalent vaccine boosters created to target omicron variants, "[vaccine effectiveness] was generally similar against BA.5-related infections [original omicron] and XBB/XBB.1.5-related infections."
OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](https://www.wsj.com/market-data/quotes/MRNA), [Pfizer](https://www.wsj.com/market-data/quotes/PFE) and [BioNTech](https://www.
Moderna Pfizer and its partner BioNTech are among the biggest losers in the healthcare sector this year, dropping more than 25% each. The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane. Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech.
Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).
With its stock down 8.4% over the past week, it is easy to disregard Moderna (NASDAQ:MRNA). However, a closer look at...
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL.
You'd have a lot more money, but only if you resisted the temptation to take the initial profits.
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China," a spokesperson said in response to a query from Reuters.
BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China," a company spokesperson said in response to a query from Reuters.
Three years since the pandemic upended the economy, here are the Massachusetts public companies that made it through in the best — and worst — shape.
The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...
Insider buying, or the legal, reported purchase of shares in a company by its C-suite/board members/large shareholders, is considered a bullish signal. However, does that mean it is best to sell/avoid stocks insiders are selling? Put simply, it depends. Heavy insider selling, or even a lack of insider buying, can sometimes be a sign that those most “in the know” at a company are not very confident in its future prospects. Then again, much like with “outsider” investors, lack of confidence isn’t
A life sciences company in Durham has secured a major partnership to discover new gene therapy treatments.
The Moving Average Convergence Divergence (MACD) oscillator is below the zero line telling us that MRNA lacks trend strength. In this daily Point and Figure chart of MRNA, below, I can see a potential upside price target in the $179 area. This weekly Point and Figure chart of MRNA, below, shows us the same $179 price target as the daily chart above.